News
GERN
3.295
-0.45%
-0.015
Weekly Report: what happened at GERN last week (0318-0322)?
Weekly Report · 3d ago
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
NASDAQ · 03/21 14:01
Geron announces pricing of $150M underwritten offering
Healthcare Geron announces pricing of $150M underwritten offering. Geron Corporation expects proceeds of ~$150M from the offering. The company expects to use the proceeds to fund the potential commercialization of imetelstat in the U.S. And EU.
Seeking Alpha · 03/19 13:21
Geron Corporation Announces Pricing Of $150M Underwritten Offering Of Common Stock And Pre-Funded Warrants
Geron Corporation announces pricing of an underwritten offering of 41,999,998 shares of its common stock. The company is a late-stage clinical biopharmaceutical company. The offering is expected to raise $150.0 million. Geron intends to use the proceeds to fund the development of imetelstat.
Benzinga · 03/19 13:07
STAT News' Adam Feuerstein Publishes "I Was Wrong About Geron's Blood Cancer Drug. Now, Is It A Takeover Target?"; Shares See Volume
I was wrong about Geron's effort to develop a blood cancer drug. The drug was never going to be approved, he says. A group of outside experts voted 12-2 in imetelstat’s favor. An FDA approval of the drug is now highly likely.
Benzinga · 03/18 13:08
Company News for Mar 18, 2024
NASDAQ · 03/18 12:48
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Nuvei Corp (NASDAQ:NVEI) rose sharply in today's pre-market trading. The company is in buyout talks with Advent International. Solidion Technology Inc. Shares gained 62.1% to $2.82 after surging around 34% on Friday.
Benzinga · 03/18 12:06
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. Stock futures were mostly higher in today's pre-market trading. The Nasdaq futures gained by around 100 points on Monday. Shares of Logitech International S.A. (NASDAQ: LOGI) fell in today’s trading. B. Riley Financial, Inc. And Geron Corporation were among the big stocks recording losses.
Benzinga · 03/18 09:57
Weekly Report: what happened at GERN last week (0311-0315)?
Weekly Report · 03/18 09:00
Inflation Squeezes Stocks, Bitcoin Slips To $68,000, While Commodities On Track For Best Week In Months: What's Driving Markets Friday?
Major stock indices continue to trade lower in Friday's session. The CBOE Volatility Index, or VIX, was up 5% after Thursday's unexpectedly high producer inflation figures. Bitcoin plunged by 5% and fell to $68,000 on Friday. Commodities shone brightly, with copper nearing a one-year-high.
Benzinga · 03/15 18:12
Geron Corp. Up Over 85%, on Pace for Largest Percent Increase Since March 2003 -- Data Talk
Geron Corporation (GERN) is currently at $3.24, up $1.50 or 85.43% from yesterday's close. Up 62.25% month-to-date, down 95.08% from its all-time closing high of $65.96 on March 1, 2000.
Dow Jones · 03/15 17:58
BUZZ-U.S. STOCKS ON THE MOVE-Emeren Group, Steel Dynamics, NYCB
Dow Jones Industrial Average was down 0.57% at 13:31 ET. Top three S&P 500 percentage gainers: CoStar Group, Steel Dynamics, NYCB. Wall Street's main stock index down on inflation figures. Emeren Group, Geron Group, and Steel Dynamics are among the top U.S. Stock losers.
Reuters · 03/15 17:47
Friday Sector Leaders: Vehicle Manufacturers, Biotechnology Stocks
NASDAQ · 03/15 17:27
Geron Price Target Raised to $5.00/Share From $4.00 by Needham
Dow Jones · 03/15 17:13
Geron Is Maintained at Buy by Needham
Dow Jones · 03/15 17:13
Needham Maintains Buy on Geron, Raises Price Target to $5
Benzinga · 03/15 17:03
VERI, STI and VERB among mid-day movers
Verb Technology Company (VERB) and Geron Corp. Among mid-day movers. Groupon, C3is and Urgently are among the companies that lost ground. VERI, STI and VERB among the biggest gainers on the day.
Seeking Alpha · 03/15 16:52
Geron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
MarketWatch · 03/15 15:50
What's Going On With Cancer Focused-Geron Stock On Friday?
FDA’s Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of Geron's imetelstat for blood cancer. The company is seeking approval for transfusion-dependent anemia in adult patients with low-to-intermediate risk myelodysplastic syndromes. Geron Corporation's shares are trading lower.
Benzinga · 03/15 15:29
Geron Is Maintained at Buy by Goldman Sachs
Dow Jones · 03/15 14:55
More
Webull provides a variety of real-time GERN stock news. You can receive the latest news about Geron Corp through multiple platforms. This information may help you make smarter investment decisions.
About GERN
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.